Michel Delforge

Teclistamab in Relapsed or Refractory Multiple Myeloma

Philippe Moreau, Alfred L. Garfall, Niels W.C.J. van de Donk et al. · New England Journal of Medicine · 2022 · 990 citations · Full text

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

Lotfi Benboubker, Meletios Α. Dimopoulos, Angela Dispenzieri et al. · New England Journal of Medicine · 2014 · 780 citations · Full text

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Ajai Chari, Dan T. Vogl, Maria Gavriatopoulou et al. · New England Journal of Medicine · 2019 · 655 citations · Full text

LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

María‐Victoria Mateos, Katja Weisel, Valerio De Stefano et al. · Leukemia · 2022 · 225 citations · Full text

Relapsed/refractory Mm, Cancer Management, Immunology +18

Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study

Peter Vandenberghe, Iwona Włodarska, Thomas Tousseyn et al. · The Lancet Haematology · 2015 · 144 citations

Lymphoid Neoplasia, Hodgkin/reed-sternberg Cells, Tumor Heterogeneity +14